CXCR2: A novel mediator of mammary tumor bone metastasis

Bhawna Sharma, Kalyan C. Nannuru, Sugandha Saxena, Michelle L. Varney, Rakesh K. Singh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Most breast cancer patients die due to bone metastasis. Although metastasis accounts for 5% of the breast cancer cases, it is responsible for most of the deaths. Sometimes even before the detection of a primary tumor, most of the patients have bone and lymph node metastasis. Moreover, at the time of death, breast cancer patients have the bulk of the tumor burden in their bones. Therapy options are available for the treatment of primary tumors, but there are minimal options for treating breast cancer patients who have bone metastasis. C-X-C motif chemokine receptor type 2 (CXCR2) receptor-mediated signaling has been shown to play a critical role during bone-related inflammations and its ligands C-X-C motif chemokine ligand 6 (CXCL6) and 8 (CXCL8) aid in the resorption of bone during bone metastasis. In this study, we tested the hypothesis that CXCR2 contributes to mammary tumor-induced osteolysis and bone metastasis. In the present study, we examined the role of both tumor cell-derived and host-derived CXCR2 in influencing mammary tumor cell bone metastasis. For understanding the role of tumor cell-derived CXCR2, we utilized Cl66 CXCR2 knockdown (Cl66-shCXCR2) and Cl66-Control cells (Cl66-Control) and observed a significant decrease in tumor growth and tumor-induced osteolysis in Cl66-shCXCR2 cells in comparison with the Cl66-Control cells. Next, for understanding the role of host-derived CXCR2, we utilized mice with genomic knockdown of CXCR2 (Cxcr2−/−) and injected Cl66-Luciferase (Cl66-Luc) or 4T1-Luciferase (4T1-Luc) cells. We observed decreased bone destruction and metastasis in the bone of Cxcr2−/− mice. Our data suggest the importance of both tumor cell-and host-derived CXCR2 signaling in the bone metastasis of breast cancer cells.

Original languageEnglish (US)
Article number1237
JournalInternational journal of molecular sciences
Volume20
Issue number5
DOIs
StatePublished - Mar 2019

Fingerprint

CXC Chemokines
Chemokine Receptors
metastasis
bones
Tumors
Bone
tumors
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
breast
cancer
Cells
Neoplasms
Osteolysis
Luciferases
Chemokine CXCL6
cells
death
mice

Keywords

  • Bone microenvironment
  • CXCR2
  • Metastasis

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

CXCR2 : A novel mediator of mammary tumor bone metastasis. / Sharma, Bhawna; Nannuru, Kalyan C.; Saxena, Sugandha; Varney, Michelle L.; Singh, Rakesh K.

In: International journal of molecular sciences, Vol. 20, No. 5, 1237, 03.2019.

Research output: Contribution to journalArticle

Sharma, Bhawna ; Nannuru, Kalyan C. ; Saxena, Sugandha ; Varney, Michelle L. ; Singh, Rakesh K. / CXCR2 : A novel mediator of mammary tumor bone metastasis. In: International journal of molecular sciences. 2019 ; Vol. 20, No. 5.
@article{f367172a30e342c4a344a1b2e5f26e49,
title = "CXCR2: A novel mediator of mammary tumor bone metastasis",
abstract = "Most breast cancer patients die due to bone metastasis. Although metastasis accounts for 5{\%} of the breast cancer cases, it is responsible for most of the deaths. Sometimes even before the detection of a primary tumor, most of the patients have bone and lymph node metastasis. Moreover, at the time of death, breast cancer patients have the bulk of the tumor burden in their bones. Therapy options are available for the treatment of primary tumors, but there are minimal options for treating breast cancer patients who have bone metastasis. C-X-C motif chemokine receptor type 2 (CXCR2) receptor-mediated signaling has been shown to play a critical role during bone-related inflammations and its ligands C-X-C motif chemokine ligand 6 (CXCL6) and 8 (CXCL8) aid in the resorption of bone during bone metastasis. In this study, we tested the hypothesis that CXCR2 contributes to mammary tumor-induced osteolysis and bone metastasis. In the present study, we examined the role of both tumor cell-derived and host-derived CXCR2 in influencing mammary tumor cell bone metastasis. For understanding the role of tumor cell-derived CXCR2, we utilized Cl66 CXCR2 knockdown (Cl66-shCXCR2) and Cl66-Control cells (Cl66-Control) and observed a significant decrease in tumor growth and tumor-induced osteolysis in Cl66-shCXCR2 cells in comparison with the Cl66-Control cells. Next, for understanding the role of host-derived CXCR2, we utilized mice with genomic knockdown of CXCR2 (Cxcr2−/−) and injected Cl66-Luciferase (Cl66-Luc) or 4T1-Luciferase (4T1-Luc) cells. We observed decreased bone destruction and metastasis in the bone of Cxcr2−/− mice. Our data suggest the importance of both tumor cell-and host-derived CXCR2 signaling in the bone metastasis of breast cancer cells.",
keywords = "Bone microenvironment, CXCR2, Metastasis",
author = "Bhawna Sharma and Nannuru, {Kalyan C.} and Sugandha Saxena and Varney, {Michelle L.} and Singh, {Rakesh K.}",
year = "2019",
month = "3",
doi = "10.3390/ijms20051237",
language = "English (US)",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - CXCR2

T2 - A novel mediator of mammary tumor bone metastasis

AU - Sharma, Bhawna

AU - Nannuru, Kalyan C.

AU - Saxena, Sugandha

AU - Varney, Michelle L.

AU - Singh, Rakesh K.

PY - 2019/3

Y1 - 2019/3

N2 - Most breast cancer patients die due to bone metastasis. Although metastasis accounts for 5% of the breast cancer cases, it is responsible for most of the deaths. Sometimes even before the detection of a primary tumor, most of the patients have bone and lymph node metastasis. Moreover, at the time of death, breast cancer patients have the bulk of the tumor burden in their bones. Therapy options are available for the treatment of primary tumors, but there are minimal options for treating breast cancer patients who have bone metastasis. C-X-C motif chemokine receptor type 2 (CXCR2) receptor-mediated signaling has been shown to play a critical role during bone-related inflammations and its ligands C-X-C motif chemokine ligand 6 (CXCL6) and 8 (CXCL8) aid in the resorption of bone during bone metastasis. In this study, we tested the hypothesis that CXCR2 contributes to mammary tumor-induced osteolysis and bone metastasis. In the present study, we examined the role of both tumor cell-derived and host-derived CXCR2 in influencing mammary tumor cell bone metastasis. For understanding the role of tumor cell-derived CXCR2, we utilized Cl66 CXCR2 knockdown (Cl66-shCXCR2) and Cl66-Control cells (Cl66-Control) and observed a significant decrease in tumor growth and tumor-induced osteolysis in Cl66-shCXCR2 cells in comparison with the Cl66-Control cells. Next, for understanding the role of host-derived CXCR2, we utilized mice with genomic knockdown of CXCR2 (Cxcr2−/−) and injected Cl66-Luciferase (Cl66-Luc) or 4T1-Luciferase (4T1-Luc) cells. We observed decreased bone destruction and metastasis in the bone of Cxcr2−/− mice. Our data suggest the importance of both tumor cell-and host-derived CXCR2 signaling in the bone metastasis of breast cancer cells.

AB - Most breast cancer patients die due to bone metastasis. Although metastasis accounts for 5% of the breast cancer cases, it is responsible for most of the deaths. Sometimes even before the detection of a primary tumor, most of the patients have bone and lymph node metastasis. Moreover, at the time of death, breast cancer patients have the bulk of the tumor burden in their bones. Therapy options are available for the treatment of primary tumors, but there are minimal options for treating breast cancer patients who have bone metastasis. C-X-C motif chemokine receptor type 2 (CXCR2) receptor-mediated signaling has been shown to play a critical role during bone-related inflammations and its ligands C-X-C motif chemokine ligand 6 (CXCL6) and 8 (CXCL8) aid in the resorption of bone during bone metastasis. In this study, we tested the hypothesis that CXCR2 contributes to mammary tumor-induced osteolysis and bone metastasis. In the present study, we examined the role of both tumor cell-derived and host-derived CXCR2 in influencing mammary tumor cell bone metastasis. For understanding the role of tumor cell-derived CXCR2, we utilized Cl66 CXCR2 knockdown (Cl66-shCXCR2) and Cl66-Control cells (Cl66-Control) and observed a significant decrease in tumor growth and tumor-induced osteolysis in Cl66-shCXCR2 cells in comparison with the Cl66-Control cells. Next, for understanding the role of host-derived CXCR2, we utilized mice with genomic knockdown of CXCR2 (Cxcr2−/−) and injected Cl66-Luciferase (Cl66-Luc) or 4T1-Luciferase (4T1-Luc) cells. We observed decreased bone destruction and metastasis in the bone of Cxcr2−/− mice. Our data suggest the importance of both tumor cell-and host-derived CXCR2 signaling in the bone metastasis of breast cancer cells.

KW - Bone microenvironment

KW - CXCR2

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=85062992771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062992771&partnerID=8YFLogxK

U2 - 10.3390/ijms20051237

DO - 10.3390/ijms20051237

M3 - Article

C2 - 30871004

AN - SCOPUS:85062992771

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 5

M1 - 1237

ER -